Instil Bio Announced Global Registrational Strategy For PD-L1xVEGF Bispecific Antibody SYN-2510/IMM2510 In Combination With Chemotherapy In Front-line Non-small Cell Lung Cancer And In Front-line Triple-negative Breast Cancer
Benzinga Newsdesk 2 years ago
BiotechNewsHealth CareGeneral
Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC).Global registrational strategy in first-line triple-negative breast cancer (TNBC).Initiation of Phase 1b/2
- Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC).
- Global registrational strategy in first-line triple-negative breast cancer (TNBC).
- Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC anticipated in late 2024 in China.
- Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line TNBC anticipated in early 2025 in China.
- US IND submission for SYN-2510 targeted in late 2024, starting with Phase 2 trial of SYN-2510 monotherapy in second-line NSCLC.